

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

RECEIVED
CENTRAL FAX CENTER
MAY 12 2006

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Date:

May 12, 2006

Recipient:

Examiner David S. Romco

Company:

USPTO

Fax Number:

571-273-8300

Voice Number:

571-272-0851

Sender:

Edward R. Ergenzinger, Reg. No.
47,549

Message:

Appl. No.: 09/005,318

Confirmation No.: 2353

Applicant(s): Hein *et al.*

Filed: January 9, 1998

Art Unit: 1647

Examiner: David S. Romco

Title: NOVEL EPITHELIAL TISSUE TARGETING AGENT

Docket No.: 040989/283662 (formerly 310098401C1)

Customer No.: 00826

Documents Attached: Interview Summary (2 pages)

Number of Pages: (including cover page)

3

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT 919-862-2221.

USER CODE:	ERGEE	REQUESTED BY:	Lynda, 2233
CLIENT/MATTER:	040989/283662	OPERATOR:	

RTA01/2197442v1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 09/005,318 Confirmation No.: 2353
Applicant(s): Hein *et al.*
Filed: January 9, 1998
Art Unit: 1647
Examiner: David S. Romeo
Title: NOVEL EPITHELIAL TISSUE TARGETING AGENT

RECEIVED
CENTRAL FAX CENTER
MAY 12 2006

Docket No.: 040989/283662 (formerly 310098401C1)
Customer No.: 00826

May 12, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INTERVIEW SUMMARY

Sir:

A telephonic interview in the above-referenced matter occurred on April 25, 2006 between Examiner David S. Romeo and Applicants' representative Edward Ergenzinger. Applicants' representative provides below a summary of the interview.

The Advisory action mailed April 6, 2005 was discussed regarding reasons for non-entry Applicants' Amendment After Final. The Examiner suggested replacing the phrase "at least one biological agent" in claim 42 with the term "an antibody". The Examiner also indicated that limiting the claims to "a J chain encoded by nucleotides 1-213 of SEQ ID NO: 8" would be free of the prior art of record. The Examiner also suggested that the claims would be allowable if the term "portion thereof" was cancelled from the independent claims. The Examiner indicated that these changes to the claims could possibly be made by an Examiner's Amendment if all other claims were in condition for allowance.


It is not believed that extensions of time or fees for net addition of claims are required. However, in the event that extensions of time are necessary to allow consideration of this paper,


RTA01/2205416v1

In re: Hein *et al.*
Appl. No.: 08/782,481
Summary of April 25, 2006 Interview

such extensions are hereby petitioned under 37 C.F.R. §1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,


Edward R. Ergenzinger
Registration No. 47,549

<p>Customer No. 00826 ALSTON & BIRD LLP Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260</p>	<p>CERTIFICATION OF FACSIMILE TRANSMISSION</p> <p>I hereby certify that this paper is being facsimile transmitted to the US Patent and Trademark Office at facsimile number 571-273-8300 on the date shown below.</p> <p> <u>May 12, 2006</u> Lynda Jo Pixley Date</p>
---	--